Navigation Links
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Date:9/4/2007

nse drug ISIS 325568 for type 2 diabetes. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... Apnea Sciences ( www.apneasciences.com ) announced it ... Aliso Viejo , California.  Jimmy Fallon , ... and worldwide expansion, a new facility with expanded infrastructure ... snore cure have exceeded our expectations and thus required ... in 23 countries and will be increasing to 39 ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... , ROCKVILLE, Md. , Feb. ... new data from a clinical study that began in May of ... Novavax,s trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched ... A/ Brisbane /59/2007, H3N2 A/ Brisbane /10/2007, and B/ Florida /04/2006 ...
... , SAN DIEGO , Feb. 8 ... of patient safety solutions that help to eliminate hospital-based medical ... in Series B-1 financing. The financing was led by ... global private equity firm, TPG Capital. Co-leads for this financing ...
Cached Medicine Technology:NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults 2NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults 3NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults 4PatientSafe Solutions, Inc. Closes $30 Million Financing 2PatientSafe Solutions, Inc. Closes $30 Million Financing 3
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 DW-InductionHeating.com (DaWei ... in designing, researching and developing, producing and marketing of ... of the business announces their new series of ... manager of the company, induction brazing refers ... a special filler material and heat. The manager says ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... ... rage. Today more than ever, people are turning to books on attaining success to help ... together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn the ... , ...
... As ... complete, three-part, self-treatment acupressure kit for the body. The Kit will include an acupressure ... ... June 28, 2010 -- As of today, the exclusive U.S. distributors of The ...
... for measles, mumps, rubella and chickenpox (MMRV) is associated ... to 2-year-old children compared with same-day administration of the ... varicella (V) vaccine for chicken pox, according to a ... the journal Pediatrics . A febrile seizure is ...
... HealthDay Reporter , SUNDAY, June 27 (HealthDay News) -- ... linked with a predisposition for type 2 diabetes, bringing the ... 38. At this point, the findings don,t mean ... lead to better treatments. "From here, to apply this ...
... ... Tarot Professionals Ltd establishes Tarosophy® Tarot Houses worldwide for ... prepared to warn Tarot readers by highlighting certification scams, bad practice ... Tarot Professionals Ltd continues to introduce innovative Tarot courses – join ...
... 26 Elevated blood levels of high-density lipoprotein (HDL) ... disease, may do the opposite in women with type ... School of Public Health study being presented at the ... The study, abstract number 0098-OR, included 658 men and ...
Cached Medicine News:Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:Yantra Mat USA Introduces the Yantra Kit: Bringing the Health Benefits of Acupressure to the Entire Body 2Health News:Combination MMRV vaccine linked with 2-fold risk of seizures 2Health News:Combination MMRV vaccine linked with 2-fold risk of seizures 3Health News:More Genes Implicated in Type 2 Diabetes 2Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 2Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 3Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 4Health News:Can too much HDL be harmful to women with type 1 diabetes? 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: